Document Classification

Section Type: RESULTS

Text: At final assessment, mirabegron was significantly superior to placebo in terms of mean [sd] change from baseline in number of micturitions/24h (-1. 67 [2. 212] vs -0. 86 [2. 354] ; P < 0. 001) and mean [sd] change from baseline in number of urgency episodes/24h (-1. 85 [2. 555] vs -1. 37 [3. 191] ; P = 0. 025), incontinence episodes/24h (-1. 12 [1. 475] vs -0. 66 [1. 861] ; P = 0. 003), urgency incontinence episodes/24h (-1. 01 [1. 338] vs -0. 60 [1. 745] ; P = 0. 008), and volume voided/micturition (24. 300 [35. 4767] vs 9. 715 [29. 0864] mL ; P < 0. 001).